Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03303521 · ClinicalTrials.gov registry record · Phase 3
A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 196
- Enrollment target
NCT03303521 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 196 participants.
The verdict
NCT03303521, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 196 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of ZS in the treatment of hyperkalemia in patients on hemodialysis.
Interventions
- DRUG Placebo
- DRUG Sodium Zirconium Cyclosilicate (ZS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2017-12-14 |
| Est. Completion | 2018-11-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03303521
The ClinicalTrials.gov registry entry for NCT03303521 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03303521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03303521 about?
NCT03303521 is a clinical study titled "A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.". The purpose of this study is to evaluate the efficacy of ZS in the treatment of hyperkalemia in patients on hemodialysis.
What is the current status of trial NCT03303521?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 196 participants. The study started on 2017-12-14. Estimated completion is 2018-11-07.
What interventions are being tested in trial NCT03303521?
The interventions under investigation include: Placebo (DRUG), Sodium Zirconium Cyclosilicate (ZS) (DRUG).
Who is sponsoring clinical trial NCT03303521?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.